Merdad Parsey, MD, PhD | Gilead
WEBMerdad Parsey, MD, PhD, is Gilead’s Chief Medical Officer, responsible for overseeing the company’s global clinical development and medical affairs organizations. He supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of ...
Board of Directors | Gilead
WEBMeet the Gilead Senior Management team and the board of directors and learn more about their roles within Gilead Sciences, Inc. Science. Science. Therapeutic Areas. Therapeutic Areas. Virology. Virology. HIV. Viral Hepatitis. COVID-19 and Emerging Viruses. Oncology. Inflammation. Pipeline. Research. Research.
Gilead Sciences’ Approach to Research & Drug Discovery
WEBWe foster a collaborative, curious and creative culture rooted in scientific exploration. Gilead researchers are empowered to pursue extraordinary discoveries and make a transformative impact on the world. Powered by innovation, our R&D teams are driven to generate advances in drug discovery, out-innovate current therapeutics and help patients ...
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
WEBJul 17, 2024 · Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this transition over the next several months.
Gilead’s Innovative HIV Treatment Research Pipeline Aims to …
WEBFOSTER CITY, Calif., March 05, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBFOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Bulevirtide Combined with Pegylated Interferon for Chronic …
WEBJun 6, 2024 · In this phase 2b trial, treatment with bulevirtide daily for 96 weeks, combined with weekly peginterferon alfa-2a therapy for the first 48 weeks, resulted in a higher percentage of patients ...
Gilead Sciences - Wikipedia
WEBGilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Inside the Innovation: Oncology Leaders | Stories@Gilead
WEBOct 28, 2021 · Oncology leaders Daejin Abidoye and Oriana Wiklund discuss their shared goal of advancing treatments and shed light on what it’s like working at Gilead.
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
WEBJul 17, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year.
Skip to content